Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tramadol extended-release tablets.

Philip I Hair1, Monique P Curran, Susan J Keam

  • 1Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|November 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Icotrokinra: First Approval.

Drugs·2026
Same author

Ferric Maltol: Pediatric First Approval.

Paediatric drugs·2026
Same author

Sevabertinib: First Approval.

Drugs·2026
Same author

Retlirafusp Alfa: First Approval.

Drugs·2026
Same author

Zeprumetostat: First Approval.

Drugs·2025
Same author

Brensocatib: First Approval.

Drugs·2025
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Extended-release tramadol (tramadol ER) offers effective once-daily pain relief for chronic osteoarthritis pain. Clinical trials show tramadol ER significantly reduces pain and improves function compared to placebo.

Area of Science:

  • Pharmacology
  • Pain Management
  • Osteoarthritis Treatment

Background:

  • Tramadol is a synthetic opioid analgesic.
  • Extended-release tramadol (tramadol ER) enables once-daily dosing.
  • Tramadol ER demonstrates comparable bioavailability to immediate-release tramadol with improved pharmacokinetic profile.

Purpose of the Study:

  • To evaluate the efficacy and safety of extended-release tramadol (tramadol ER) for chronic pain in osteoarthritis patients.
  • To compare tramadol ER with placebo in managing moderate to moderately severe osteoarthritis pain.

Main Methods:

  • Randomised, double-blind, placebo-controlled trials were conducted.
  • Studies involved patients with osteoarthritis of the knee and/or hip.
  • Pain intensity and physical function were assessed using validated scales over 12 weeks.

Related Experiment Videos

Main Results:

  • Tramadol ER was significantly more effective than placebo in reducing pain intensity.
  • Patients receiving tramadol ER showed significant improvements in pain and physical function scores.
  • Common adverse events included dizziness, nausea, constipation, and somnolence.

Conclusions:

  • Extended-release tramadol is an effective treatment option for moderate to moderately severe chronic osteoarthritis pain.
  • Once-daily tramadol ER provides sustained pain relief and functional improvement.
  • The safety profile of tramadol ER is consistent with its known adverse event profile.